X

Trial Profile

A Phase 1 Study of DVX201, an Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DVX 201 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Coeptis Therapeutics

Most Recent Events

05 Sep 2024 According to a Coeptis Therapeutics media release, publication of Phase 1 results for DVX201 trial in hospitalized COVID-19 patients; currently under peer review
13 Mar 2024 Status changed from active, no longer recruiting to completed.
04 Jan 2024 Interim results presented in a Coeptis Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com